Erwin R. Boghaert
Wyeth Research
10965 Pearl River
USA
Name/email consistency: high
- The oncofetal protein, 5T4, is a suitable target for antibody-guided anti-cancer chemotherapy with calicheamicin. Boghaert, E.R., Sridharan, L., Khandke, K.M., Armellino, D., Ryan, M.G., Myers, K., Harrop, R., Kunz, A., Hamann, P.R., Marquette, K., Dougher, M., DiJoseph, J.F., Damle, N.K. Int. J. Oncol. (2008)
- Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy. Boghaert, E.R., Khandke, K., Sridharan, L., Armellino, D., Dougher, M., Dijoseph, J.F., Kunz, A., Hamann, P.R., Sridharan, A., Jones, S., Discafani, C., Damle, N.K. Int. J. Oncol. (2006)
- Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xenografts. Boghaert, E.R., Sridharan, L., Armellino, D.C., Khandke, K.M., DiJoseph, J.F., Kunz, A., Dougher, M.M., Jiang, F., Kalyandrug, L.B., Hamann, P.R., Frost, P., Damle, N.K. Clin. Cancer Res. (2004)